No abstract

≤ 60 years) and lower for patients with a high comorbidity score (HR 1.13; 95%CI 1.05-1.60 for CCI score 3-5 compared to CCI score ≤ 2). We found a high variation of persistence between different drugs. ConClusions: Japanese RA patients have a high persistence rate of biologic treatments. However, multi-factors affect the persistence rate of Japanese patients including age, comorbidities and patient type. Naïve patients tend to have high persistence rate than continuing biologic patients.

No abstract